Trial Profile
A Postmarket Surveillance Registry of the BioMatrix Drug-eluting Stent
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2019
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions
- Acronyms eBMX-PMS
- Sponsors Biosensors International Group
- 03 May 2019 Status changed from active, no longer recruiting to completed.
- 21 May 2013 New registry data were presented at EuroPCR 2013, according to a Biosensors International Group.
- 20 May 2011 Results have been presented for the first time at EuroPCR-2011 according to a Biosensors International Group media release; results were also reported in the media release.